The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study

SUMMARY: To demonstrate the clinical comparability between RGB-10 (a biosimilar teriparatide) and the originator, a comparative pharmacokinetic trial was conducted. The study was successful in establishing bioequivalence. Marketing authorisation for RGB-10 (Terrosa®) was granted by the European Medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Takács, I., Jókai, E., Kováts, D. E., Aradi, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422976/
https://www.ncbi.nlm.nih.gov/pubmed/30357438
http://dx.doi.org/10.1007/s00198-018-4741-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422976/
https://www.ncbi.nlm.nih.gov/pubmed/30357438
http://dx.doi.org/10.1007/s00198-018-4741-0

Ejemplares similares